246 related articles for article (PubMed ID: 32629564)
1. [Immuno-checkpoint inhibitor resistance and strategy in lung cancer].
Jiang WR; Fang LP; Chang N; Zhang J
Zhonghua Jie He He Hu Xi Za Zhi; 2020 Jul; 43(7):603-606. PubMed ID: 32629564
[TBL] [Abstract][Full Text] [Related]
2. KEYNOTE-024: Unlocking a pathway to lung cancer cure?
Rusch VW; Chaft J; Hellmann M
J Thorac Cardiovasc Surg; 2018 Apr; 155(4):1777-1780. PubMed ID: 29395215
[No Abstract] [Full Text] [Related]
3. There and back again: An immunotherapy tale.
Guo Y; Krupnick AS
J Thorac Cardiovasc Surg; 2018 Apr; 155(4):1771-1774. PubMed ID: 29409610
[No Abstract] [Full Text] [Related]
4. Clinical benefit to programmed death-1 inhibition for non-small-cell lung cancer is associated with higher blood eosinophil levels.
Sibille A; Henket M; Corhay JL; Louis R; Duysinx B
Acta Oncol; 2020 Mar; 59(3):257-259. PubMed ID: 31755328
[No Abstract] [Full Text] [Related]
5. Retrospect and Prospect for Lung Cancer in China: Clinical Advances of Immune Checkpoint Inhibitors.
Lu S; Yu Y; Yang Y
Oncologist; 2019 Feb; 24(Suppl 1):S21-S30. PubMed ID: 30819828
[TBL] [Abstract][Full Text] [Related]
6. New strategies in immunotherapy for lung cancer: beyond PD-1/PD-L1.
Villanueva N; Bazhenova L
Ther Adv Respir Dis; 2018; 12():1753466618794133. PubMed ID: 30215300
[TBL] [Abstract][Full Text] [Related]
7. [Predictive biomarkers for immune checkpoint inhibitors in non-small-cell lung cancer].
Fu MJ; Zhou JY
Zhonghua Jie He He Hu Xi Za Zhi; 2020 Feb; 43(2):87-91. PubMed ID: 32062877
[TBL] [Abstract][Full Text] [Related]
8. Overcoming Primary Resistance to PD-1 Inhibitor With Anti-PD-L1 Agent in Squamous-Cell NSCLC: Case Report.
Gelsomino F; Di Federico A; Filippini DM; Dall'Olio FG; Lamberti G; Sperandi F; Balacchi C; Brocchi S; Ardizzoni A
Clin Lung Cancer; 2020 Mar; 21(2):e45-e48. PubMed ID: 31902695
[No Abstract] [Full Text] [Related]
9. Finally, after decades, immune checkpoint inhibitors dethroned the standard of care of small-cell lung cancer.
Saleh K; Khalife-Saleh N; Kourie HR
Immunotherapy; 2019 Apr; 11(6):457-460. PubMed ID: 30860440
[No Abstract] [Full Text] [Related]
10. Clinical Outcomes in Patients With Metastatic Lung Cancer Treated With PD-1/PD-L1 Inhibitors and Thoracic Radiotherapy.
Hwang WL; Niemierko A; Hwang KL; Hubbeling H; Schapira E; Gainor JF; Keane FK
JAMA Oncol; 2018 Feb; 4(2):253-255. PubMed ID: 28973343
[TBL] [Abstract][Full Text] [Related]
11. Role of immune-checkpoint inhibitors in lung cancer.
Jain P; Jain C; Velcheti V
Ther Adv Respir Dis; 2018; 12():1753465817750075. PubMed ID: 29385894
[TBL] [Abstract][Full Text] [Related]
12. Use of Immunotherapy in Extensive-Stage Small Cell Lung Cancer.
Konala VM; Madhira BR; Ashraf S; Graziano S
Oncology; 2020; 98(11):749-754. PubMed ID: 32663833
[TBL] [Abstract][Full Text] [Related]
13. Immune-checkpoint inhibitor plus chemotherapy versus conventional chemotherapy for first-line treatment in advanced non-small cell lung carcinoma: a systematic review and meta-analysis.
Zhou Y; Chen C; Zhang X; Fu S; Xue C; Ma Y; Fang W; Yang Y; Hou X; Huang Y; Zhao H; Hong S; Zhang L
J Immunother Cancer; 2018 Dec; 6(1):155. PubMed ID: 30577837
[TBL] [Abstract][Full Text] [Related]
14. Current status of immune checkpoint inhibitors in treatment of non-small cell lung cancer.
Lim SW; Ahn MJ
Korean J Intern Med; 2019 Jan; 34(1):50-59. PubMed ID: 30612418
[TBL] [Abstract][Full Text] [Related]
15. Immune checkpoint blockade in small cell lung cancer.
Tay RY; Heigener D; Reck M; Califano R
Lung Cancer; 2019 Nov; 137():31-37. PubMed ID: 31525648
[TBL] [Abstract][Full Text] [Related]
16. Heterogeneity of EGFR-mutant clones and PD-L1 highly expressing clones affects treatment efficacy of EGFR-TKI and PD-1 inhibitor.
Kunimasa K; Nakamura H; Sakai K; Kimura M; Inoue T; Tamiya M; Nishino K; Kumagai T; Nakatsuka S; Endo H; Inoue M; Nishio K; Imamura F
Ann Oncol; 2018 Oct; 29(10):2145-2147. PubMed ID: 30099497
[No Abstract] [Full Text] [Related]
17. PD-1 checkpoint blockade alone or combined PD-1 and CTLA-4 blockade as immunotherapy for lung cancer?
Tanvetyanon T; Gray JE; Antonia SJ
Expert Opin Biol Ther; 2017 Mar; 17(3):305-312. PubMed ID: 28064556
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy in non-small cell lung cancer: who are the long-responders?
Fernandes AL; Alves A; Dias M; Barroso A
Anticancer Drugs; 2021 Nov; 32(10):1150-1152. PubMed ID: 34661552
[No Abstract] [Full Text] [Related]
19. Predictive biomarkers of response for immune checkpoint inhibitors in non-small-cell lung cancer.
Prelaj A; Tay R; Ferrara R; Chaput N; Besse B; Califano R
Eur J Cancer; 2019 Jan; 106():144-159. PubMed ID: 30528799
[TBL] [Abstract][Full Text] [Related]
20. Outcome of Patients with Non-Small Cell Lung Cancer and Brain Metastases Treated with Checkpoint Inhibitors.
Hendriks LEL; Henon C; Auclin E; Mezquita L; Ferrara R; Audigier-Valette C; Mazieres J; Lefebvre C; Rabeau A; Le Moulec S; Cousin S; Duchemann B; le Pechoux C; Botticella A; Ammari S; Gazzah A; Caramella C; Adam J; Lechapt E; Planchard D; De Ruysscher D; Dingemans AM; Besse B
J Thorac Oncol; 2019 Jul; 14(7):1244-1254. PubMed ID: 30780002
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]